SMART Pilot Trial of Glycemic Screening Outreach

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT06915194
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Text message — BEHAVIORAL
    Participants receive a text message encouraging glycemic screening
  • Patient portal message — BEHAVIORAL
    Participants receive a patient portal message encouraging glycemic screening
  • Mailed letter — BEHAVIORAL
    Participants receive a mailed letter encouraging glycemic screening

Study Details

Approximately 130 million Americans have prediabetes or type 2 diabetes (T2D) but remain unscreened and/or unaware of their diagnosis. While prediabetes/T2D screening, also known as glycemic screening, is endorsed in national guidelines, there is almost no research on how to increase screening rates, or evaluations of interventions testing the effectiveness of screening promotion strategies. The American Medical Association has published prediabetes quality measures that apply to UCLA Health as well as all other health systems, specifically tracking the percentage of adult patients with risk factors for T2D due for glycemic screening for whom the screening process was initiated. However, there is no current systemic effort underway at UCLA, or most other health systems, to encourage glycemic screening. We are proposing a pilot trial of the first SMART (Sequential Multiple Assignment Randomized Trial) for glycemic screening. Our SMART experiment will provide preliminary feasibility and acceptability data for a larger, multisite trial that will provide vital guidance to optimize screening approaches for a growing number of screening-eligible patients so that they may seek earlier detection, treatment, and/or access to lifestyle programs and interventions for T2D or prediabetes.

Key Dates

Start date
Jul 8, 2025
Status verified
Apr 2026
Primary completion
Oct 8, 2025
Completion
Nov 8, 2025

Study Design

Enrollment
102 participants (actual)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SCREENING

Arms

  • Experimental: Initial text, follow-up text, letter
    Participants are initially randomized to glycemic screening invitations by text, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by text. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.
  • Experimental: Initial portal, follow-up portal, letter
    Participants are initially randomized to glycemic screening invitations by patient portal, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by patient portal. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.
  • Experimental: Initial text, follow-up portal, letter
    Participants are initially randomized to glycemic screening invitations by text, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by patient portal. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.
  • Experimental: Initial portal, follow-up text, letter
    Participants are initially randomized to glycemic screening invitations by patient portal, and then if they are not screened within 30 days, then they are re-rerandomized to another glycemic screening invitation by text. If they are still not screened in another 30 days then they receive a mailed letter encouraging glycemic screening.
  • No Intervention: Usual care
    Patients do not receive any glycemic screening invitations

Primary Outcome Measure

Hemoglobin A1c [ Time Frame: 90 days ]

Locations (1)

FacilityCityStateZIP
University of California, Los AngelesLos AngelesCalifornia90024

Find similar trials in Los Angeles, CA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
University of California, Los Angeles· Los Angeles, CA

Related Studies